Sara Caputo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Sara Caputo has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
- Alberto Briganti
Vita-Salute San Raffaele University
15 shared publications - Angela Bachi
IFOM-FIRC Institute of Molecular Oncology
15 shared publications - Angelo Lombardo
San Raffaele Telethon Institute for Gene Therapy, IRCCS San Raffaele Scientific Institute, Milan, Italy
15 shared publications - Anna Sofia Tascini
Center for Omics Sciences, IRCCS Ospedale San Raffaele, Milan, Italy
15 shared publications - Arianna Brevi
IRCCS Ospedale San Raffaele 1 Cellular Immunology Unit, Division of Immunology, Transplantation and Infectious Diseases Milan, Italy
15 shared publications - Chiara Venegoni
IRCCS Ospedale San Raffaele 4 Division of Experimental Oncology/Unit of Urology, URI Milan, Italy
15 shared publications
Latest Publications
- Open Access
- 15 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 10 from Intercepting YAP Activation in Prostate Cancer Blocks Neuroendocrine Progression
Efficacy of CA-3 treatment in mouse models of PC
- 15 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 10 from Intercepting YAP Activation in Prostate Cancer Blocks Neuroendocrine Progression
Efficacy of CA-3 treatment in mouse models of PC
- Open Access
- 15 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 4 from Intercepting YAP Activation in Prostate Cancer Blocks Neuroendocrine Progression
Polarized light analysis of ECM linearization in human prostate cancer specimen
- 15 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 4 from Intercepting YAP Activation in Prostate Cancer Blocks Neuroendocrine Progression
Polarized light analysis of ECM linearization in human prostate cancer specimen
- Open Access
- 15 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Intercepting YAP Activation in Prostate Cancer Blocks Neuroendocrine Progression
Identified proteins in the mouse ECM
- 15 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Intercepting YAP Activation in Prostate Cancer Blocks Neuroendocrine Progression
Identified proteins in the mouse ECM
- Open Access
- 15 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 7 from Intercepting YAP Activation in Prostate Cancer Blocks Neuroendocrine Progression
Inhibition of α2 reduces invasiveness of PNE and PAC cells
- 15 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 7 from Intercepting YAP Activation in Prostate Cancer Blocks Neuroendocrine Progression
Inhibition of α2 reduces invasiveness of PNE and PAC cells
- Open Access
- 15 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from Intercepting YAP Activation in Prostate Cancer Blocks Neuroendocrine Progression
Adverse events in CA-3 vs vehicle treated mice
- 15 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from Intercepting YAP Activation in Prostate Cancer Blocks Neuroendocrine Progression
Adverse events in CA-3 vs vehicle treated mice
- Open Access
- 15 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Intercepting YAP Activation in Prostate Cancer Blocks Neuroendocrine Progression
Gene signatures used for transcriptomic analysis
- 15 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Intercepting YAP Activation in Prostate Cancer Blocks Neuroendocrine Progression
Gene signatures used for transcriptomic analysis
- Open Access
- 15 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 5 from Intercepting YAP Activation in Prostate Cancer Blocks Neuroendocrine Progression
Divergence of the proteomes of ECMs obtained from TRAMP and WT prostates
- 15 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 5 from Intercepting YAP Activation in Prostate Cancer Blocks Neuroendocrine Progression
Divergence of the proteomes of ECMs obtained from TRAMP and WT prostates
- Open Access
- 15 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 6 from Intercepting YAP Activation in Prostate Cancer Blocks Neuroendocrine Progression
Differentially expressed matrisome genes discriminate human NEPC and CRPC-Adeno
- 15 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 6 from Intercepting YAP Activation in Prostate Cancer Blocks Neuroendocrine Progression
Differentially expressed matrisome genes discriminate human NEPC and CRPC-Adeno
- Open Access
- 15 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 11 from Intercepting YAP Activation in Prostate Cancer Blocks Neuroendocrine Progression
CA-3 inhibits NEPC and not WT organoids
- 15 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 11 from Intercepting YAP Activation in Prostate Cancer Blocks Neuroendocrine Progression
CA-3 inhibits NEPC and not WT organoids
- Open Access
- 15 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from Intercepting YAP Activation in Prostate Cancer Blocks Neuroendocrine Progression
Signature of pre-existing CRPC-like cells segregates NEPC from adenocarcinoma in mice and humans
- 15 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from Intercepting YAP Activation in Prostate Cancer Blocks Neuroendocrine Progression
Signature of pre-existing CRPC-like cells segregates NEPC from adenocarcinoma in mice and humans